Objective: Autonomic nervous system dysfunction has the potential to adversely impact general medical health and is known to exist in a number of psychiatric disorders. It reflects alterations in the function of several regions of the central nervous system. Measurement of heart rate variability provides a non-invasive tool for studying autonomic function. While the literature relating to the technical process of heart rate variability and aspects of depressive disorders has been reviewed in the past, research relating to both depressive and bipolar disorders has not been comprehensively reviewed. This paper critically considers the published research in heart rate variability in both depressive and bipolar affective disorders.
Introduction
Changes in autonomic nervous system (ANS) activity have been linked to a variety of mood disorders, including bipolar disorders, depressive disorders, anxiety disorders and schizophrenia (Alvares et al., 2015; Gorman and Sloan, 2000; Henry et al., 2010; Kemp et al., 2014a; Moon et al., 2013; Outhred et al., 2014; Valenza et al., 2014) , and consequently a variety of cardiac disorders (Kemp and Quintana, 2013; Stapelberg et al., 2012; Stein and Kleiger, 1999) and other general medical disorders (Cygankiewicz and Zareba, 2013; Xhyheri et al., 2012) . In addition, vagal nerve stimulation (VNS) has shown promise as a treatment for severe depressive disorders (Daban et al., 2008; George et al., 2007; Rizvi et al., 2011) . Regulation of parasympathetic activity (identified as cardiac vagal tone) has also been connected to regulation of emotional reactivity, psychological flexibility and social engagement, as well as reduced prefrontal cortical activity (Geisler et al., 2013; McCraty and Childre, 2010; Porges, 2009; Sgoifo et al., 2015; Thayer et al., 2009 Thayer et al., , 2012 Thayer and Lane, 2000) . This review examines the current literature which explores the associations of the ANS with both major depressive dis-
Autonomic dysregulation and HRV
A useful, safe, convenient and non-invasive measure of autonomic activity is HRV. HRV can be measured as the variations in time between consecutive R waves on an electrocardiograph (ECG) ('Time domain measures') and decomposition of the wave form of ECG-RR intervals (interbeat intervals or RRIs) into frequency power bands using spectral analysis ('Frequency domain measures') (Rajendra Acharya et al., 2006; Voss et al., 2006) . A number of parameters are used to measure HRV (Kleiger et al., 2005; Reyes del Paso et al., 2013; Shaffer et al., 2014; Xhyheri et al., 2012) . While there is wide agreement about the interpretation of these measures, there remains some debate about the precise implications of each parameter (Heathers, 2014; Quintana and Heathers, 2014) . The most commonly used time domain measures are the standard deviation of normal to normal RRIs (SDNN), the root mean square of normal to normal interval differences (RMSSD) and the proportion of RRIs of more than 50 millisecond (pNN50). The SDNN is predominantly (but not exclusively) indicative of sympathetic activity (increasingly with the duration of ECG recordings), while the RMSSD and pNN50 are indicative of parasympathetic activity. The most common frequency domain measures are the high-frequency (HF) power band (HF = 0.15-0.4 Hz) and low-frequency (LF) power band (LF = 0.04-0.15 Hz). The HF measure is indicative of parasympathetic activity and the LF measure of a mix of sympathetic and parasympathetic activity. Total power (TP) is a broad measure of autonomic activity. HRV varies inversely with the heart rate and directly with the interbeat interval.
HRV provides a convenient tool for investigating the activity of the ANS in the pathophysiology of major mood disorders, as well as the genesis of cardiovascular and other complications associated with mood disorders and their treatment (Hanson et al., 2013; Kaplan et al., 1991; Kemp et al., 2012; Kemp and Quintana, 2013; Soares-Miranda et al., 2014; Stapelberg et al., 2012) . Measurement of HRV has the potential to offer a diagnostic tool through the identification of individuals suffering some forms of mental illness Carney et al., 2000; Kemp et al., 2010; Moon et al., 2013; Stapelberg et al., 2012; Valenza et al., 2014) . It may offer even more specificity for melancholic/somatic subtypes of depressive illness (Kemp et al., 2014b; Messerotti Benvenuti et al., 2015) , but this requires further confirmation.
The activity of the ANS is sensitive to age and gender (Thayer et al., 1998; Voss et al., 2013) , physical activity (Perini and Veicsteinas, 2003; Routledge et al., 2010) , alcohol consumption (Kemp and Quintana, 2013; Romanowicz et al., 2011; Sagawa et al., 2011) , nicotine (Munjal et al., 2009 ), food and water intake (Quintana and Heathers, 2014) , circadian rhythm (Boudreau et al., 2013; Tobaldini et al., 2013) , heart rate (prominently around 60 bpm or less) (Billman, 2013; Sacha and Pluta, 2008), blood pressure (Kleiger et al., 2005) and several medications (Hanson et al., 2013; Kemp et al., 2014a; Kemp and Quintana, 2013; O'Regan et al., 2014; Stapelberg et al., 2012) . HRV is also highly sensitive to respiration, including respiratory rate, respiratory depth and respiratory sinus arrhythmia (RSA) (Heathers, 2014; Perakakis et al., 2009; Quintana and Heathers, 2014; Schafer and Vagedes, 2013; Shaffer et al., 2014) . Regulating the frequency and depth of respiration reduces this contribution to HRV (Quintana and Heathers, 2014) . However, the number and complexity of the confounding variables which contribute to HRV make the collection of data from this parameter difficult and interpretation open to question. Designing research methodology to minimize these confounding variables and analysing the data to adjust for unavoidable confounding variables are critically important challenges in this area of study.
The ANS functions in a non-linear fashion, with the parasympathetic system approaching chaotic activity (Voss et al., 2006) . Non-linear measures offer, potentially, more valid interpretations of ANS activity than the linear measures discussed above and are less sensitive to confounding variables (Kaplan et al., 1991; Kemp et al., 2010; Voss et al., 2006) .
HRV and bipolar disorder
Research into mania has revealed considerable evidence of reduction in many HRV parameters and particularly parasympathetic activity, although the findings are not fully consistent. Henry et al. (2010) studied HRV in 23 hospitalized subjects with current mania and 23 healthy controls, using brief ECG recordings. The severity of illness was considered to be 'moderate', using the criteria of Leucht et al. (2005) and Lukasiewicz et al. (2013) , and the age range was between 18 and 55 years, inclusive. Subjects with mania exhibited non-significantly higher mean heart rates but reductions in SDNN. In contrast, the HF score was significantly higher in the manic patients, although so was the LF/HF ratio. Measures of the RMSSD and pNN50 were lower in the manic patients compared with the controls. Apart from a small decrease in LF/HF ratio with lithium use, there were no significant differences in measures related to mood stabilizer or antipsychotic use. Similarly, Moon et al. (2013) studied HRV in 41 subjects with bipolar affective disorder (manic phase), 34 with MDD, 35 with schizophrenia and 27 healthy control subjects. The manic subjects were reported to have Young Mania Rating Scale (YMRS) mean scores of 19.15 ± 8.58. They were all taking mood stabilizers and/or atypical antipsychotic medications. A brief ECG was recorded and the SDNN, RMSSD, TP, LF and HF measures were all lower in the manic subjects.
Only the HF scores were reduced in MDD. There were no significant differences in Approximate Entropy in either group. The authors suggested that the relatively 'extreme affective lability' in the bipolar patients may have contributed to the changes in HRV reported. In 2014, Chang et al. (2014) found that 61 unmedicated patients with mania, compared with 183 healthy control subjects, exhibited lower mean and variance of RRIs (similar in significance to the SDNN) and lower LF and HF spectral power. However, the LF/HF ratios were higher, and both YMRS total scores were positively correlated with LF/HF ratio and negatively correlated with HF measures. These observations suggest that during unmedicated mania, HRV was significantly disrupted and the trend was towards higher sympathetic and lower parasympathetic activity. Chang et al. (2015) examined HRV using 5-minute, supine ECG recordings (with standardized respiratory rate) in 116 unmedicated subjects with bipolar II disorder (currently depressed), 591 with MDD (also unmedicated) and 421 control subjects. The bipolar and unipolar depressed subjects were significantly older than the controls. The measures of HRV revealed that the bipolar subjects exhibited lower total variance, HF, LF and very-low-frequency (VLF) scores than the depressed subjects, and both were lower than the control subjects. They suggested that HRV measures might assist separation of unipolar and bipolar depression, but these findings await confirmation. Outhred et al. (2014) summarized the association of bipolar spectrum disorder with disturbances in prefrontal and limbic network neural activity, early neural processing and ANS dysregulation. They commented upon the significant technical variations and limitations in the research they reviewed, as well as the diagnostic heterogeneity and medication use, but noted significant evidence of reduced autonomic activity in these disorders. Quintana et al. (2015) found significant reduction in 33 subjects suffering from bipolar disorders and 47 suffering from schizophrenia, with varying severity of symptoms, compared with 212 healthy controls. Cohen et al. (2003) recorded HRV using brief ECG recordings in 39 euthymic bipolar I and 39 healthy control subjects. The SDNN, TP and LF/HF ratios were significantly lower in the bipolar subjects than controls, and HF power was higher, suggesting a reduction in the sympathovagal ratio. Re-analysis of the data using non-linear mathematical procedures found no significant differences between the groups (Todder et al., 2005) . Gruber et al. (2011) recorded parasympathetic activity using HF scores in 23 euthymic bipolar subjects, compared with 24 controls, and reported a significant difference. The data showed identical mean values but with large variations. Latalova et al. (2013) reported in a 'Letter to the Editor' a study of HRV in 23 subjects with remitted bipolar affective disorder (subtype unspecified). Brief ECG recordings were collected and HRV analysis included calculation of time domain variables, frequency domain variables and 'non-linear analyses'. A reduction in 'most' (unspecified) parameters of ANS function was reported, but multiple methodological deficiencies left this report difficult to interpret. Lee et al. (2012) addressed the association of 'subsyndromal' bipolar depression and HRV. HRV measures from brief ECG recordings in bipolar subjects (10 males and 23 females) and healthy controls (23 males and 36 females) were employed. The Montgomery-Asberg Depression Rating Scale (MADRS) score in bipolar subjects was 3.8 ± 3.7 (mean ± standard deviation), and the Clinical Global Impression-Severity Scale (CGI-S) score was 1.6 ± 0.7 (very low). The bipolar patients were found to have lower HRV measures using the SDNN, pNN50 and log TP. Negative correlations were found between the CGI-S score and SDNN, RMSSD, pNN50, LF and HF powers. They concluded that sub-syndromal bipolar depression (not full remission) was accompanied by reduced HRV.
HRV and euthymia in bipolar disorders
More recently, Voggt et al. (2015) used 30-minute ECG recordings in 90 predominantly medicated bipolar I and II subjects combined, deemed 'clinically stable', and 62 healthy control subjects, to measure differences in HRV. They found that the SDNN, LF and HF parameters were lower in the bipolar subjects. The contribution by medication use (a very significant confounding variable) was not included in their multivariate analysis (multi-linear regression).
HRV and depressive disorder
The research on HRV in depressive disorders has already been reviewed by a number of authors, but it is helpful to summarize those findings and update the literature since their publication. The evidence for parasympathetic dysregulation in depressive disorders was critically assessed by Rottenberg (2007) in a meta-analysis of 13 cross-sectional studies. He concluded that depression only contributed a small to medium effect size impact upon cardiac vagal control, and only explained about 2% of the variance, with a 'small to medium' overall effect size (Cohen's d = 0.332). However, the overall difference between depressed subjects and healthy controls was significant (t = 4.26 and p < 0.001) and the range of Cohen's d for individual studies was from 0.83 to −0.078. Subsequently, Kemp et al. (2010) performed a meta-analysis of 18 studies, which examined HRV in 673 patients with MDD and 407 healthy control subjects. Those with depression had lower HRV time-based measures, higher 'high-frequency' power measures and higher Valsalva ratios than controls. Non-linear measures (probably more reliable than linear measures) indicated a negative correlation of depression severity and HRV. Tricyclic antidepressants were associated with decreased HRV, while selective serotonin reuptake inhibitors (SSRIs), mirtazapine and nefazodone, had no significant effects. In 2012, Stapelberg et al. (2012) reviewed the literature relating to HRV in MDD and found further evidence consistent with reduced parasympathetic activity, although they noted that the results were confounded by the use of medications. Kemp et al. (2012) used brief ECG sampling in nonmedicated depressed subjects, including 24 without anxiety, 24 with generalized anxiety disorder and 14 with panic disorder or post-traumatic stress disorder, compared with 94 age-and sex-matched control subjects. They found significantly reduced RMSSD and HF measures in the depressed subjects with comorbid generalized anxiety. The LF/HF ratios were higher in those subjects, but this is of uncertain significance (Billman, 2013; Reyes del Paso et al., 2013; Shaffer et al., 2014) . Wang et al. (2013) , in a carefully designed study, examined a number of HRV variables in 53 MDD subjects (of at least moderate severity) and 53 healthy subjects, matched for age and sex. Using 24-hour ECG recordings, they found SDNN, SDANN (standard deviation of the average normal to normal intervals), RMSSD and pNN50 measures, as well as HF power, were all significantly lower in the depressed subjects. The LF/HF ratios positively correlated with severity of depression, but, as noted above, this ratio is of uncertain significance. Brunoni et al. (2013) observed the effects of treatment for depression using sertraline or direct electric current therapy (tDCS) upon HRV, with 118 moderately depressed subjects and matched controls. The lower HRV measures in their depressed subjects did not change with positive clinical response to either treatment modality. They suggested that reduction in HRV in depressive disorder may be a biomarker of depression. Sgoifo et al. (2015) came to a similar conclusion in their review of the literature regarding autonomic dysregulation and depressive disorders. These conclusions await further confirmation. Ahrens et al. (2008) found no differences in HRV measures (mainly frequency) in 22 recurrently depressed female subjects, in remission, compared with 20 control subjects (aged 51 ± 1.7 years). The ECG recordings were very brief and HRV measures limited to frequency data. The results are therefore limited in significance. However, Ha et al. (2015a) in a study of 30 predominantly female, 'newly' depressed and medication-free subjects (mean age: 65 ± 5 years) exhibited lower high, low and total frequency HRV measures, as well as lower SDNN, RMSSD and pNN50, than 30 matched controls. Shinba (2013) also studied the reactivity of HRV during depressive episodes in a group of 22 unmedicated depressed subjects, compared with 47 age-and gender-matched control subjects, during a cognitive challenge task. They found an increase in HF power and LF/HF ratio during and after the challenge, suggesting increased parasympathetic and possibly increased sympathetic activity in depressed subjects during a cognitive stress. However, the number of depressed subjects was small and the use of a cognitive challenge makes this study significantly different from those performed at rest.
In a study using 15,105 subjects and carefully considered methodology, Kemp et al. (2014a) found that depressive illness was not associated with reduction in measures of HRV, but recognized that the study population was heterogeneous and confounding variables may have distorted their findings in this group. Subsequently, Kemp et al. (2014b) confirmed the significance of the heterogeneity by finding lower HRV (measured as RMSSD) in subjects suffering from MDD with melancholia (n = 40) than in a nonmelancholic cohort (n = 32). Messerotti Benvenuti et al. (2015) found a significant association between somatic symptoms of depression (using the Beck Depression Inventory II) and reduced HRV, measured by SDNN, NN50 and TP (but not RMSSD). However, their study population consisted of 62 healthy college students, and only the 25 students deemed to suffer dysphoric symptoms exhibited this association. Cognitive and affective symptoms of depression were not associated with changes in HRV. Their findings are of interest as they confirm an association of reduced HRV with somatic symptoms of depression (some similarities to melancholia) but are limited by the absence of actual depressive disorders in their subject cohort. Ha et al. (2015b) reported that in 30 antidepressant-free subjects aged more than 60 years, compared with 30 healthy age-and sex-matched subjects, recently diagnosed depression was associated with reduced LF and HF power, TP, VLF power, SDNN, RMSSD and pNN50 measures. The severity of depression was moderate, with MADRS scores of 24.6 ± 5.
HRV, sleep and mood disorders
As disruption of sleep is highly significant in major mood disorders, promotes relapse, contributes significantly to impaired function (Boland and Alloy, 2013; Boudebesse et al., 2014; Goodwin et al., 2007; Harvey et al., 2005; Murray and Harvey, 2010; Pandi-Perumal and Kramer, 2010; Paykel et al., 1995; St-Amand et al., 2013; Yatham and Maj, 2010) and HRV exhibits a circadian rhythm (Boudreau et al., 2011 (Boudreau et al., , 2012 (Boudreau et al., , 2013 , the associations of HRV with sleep and mood disorders are considered.
In healthy sleep, the sympathovagal balance is tipped towards parasympathetic activity around sleep onset and during sleep stages I, II, III and IV (Bianchi and Mendez, 2013; Busek et al., 2005; Cabiddu et al., 2012; Chouchou and Desseilles, 2014) . Conversely, the sympathovagal balance is reversed during rapid eye movement (REM) sleep (Busek et al., 2005; Chouchou and Desseilles, 2014) . All autonomic activity falls during stages III and IV, but perhaps with a greater fall in sympathetic than parasympathetic activity (Boudreau et al., 2013; Goldberger et al., 2001) .
Australian & New Zealand Journal of Psychiatry, 50 (6) The sympathovagal imbalance reported in patients with mood disorders during 24-hour, bedtime and sleep studies may in part be related to the relative increase in REM-stage sleep duration reported in these disorders (Palagini et al., 2013; Pandi-Perumal and Kramer, 2010; Paykel et al., 1995) . Yang et al. (2011) reported a study of ambulant 24-hour HRV measures (including multiscale entropy) in 52 non-medicated patients with MDD, 47 non-medicated patients with primary insomnia and 88 matched control subjects. The 'sleep' process was included in the ECG record of the 'bedtime' period. Subjects with current MDD and primary insomnia exhibited significant reductions in HRV indices (consistent with reduced parasympathetic activity) and reduced physiologic complexity, compared with the control subjects. The differences in HRV measures also correlated with poor sleep quality (Pittsburgh Sleep Quality Index and the Epworth Sleepiness Scale), but not with the measures of depressive symptoms (Beck Depression Inventory and Hamilton Depression Rating Scale). This confirmed that insomnia contributed to adverse changes in autonomic function, independent of depressive symptoms. Migliorini et al. (2011) reported a study of HRV during sleep in one subject with bipolar affective disorder (aged 37 years, type I disorder) and eight healthy control subjects (aged 18-45 years). The study followed a complex design, with the bipolar subject observed over four nights and the control subjects for one night each. The bipolar subject's mean heart rate, SDNN and RMSSD were lower than the mean of all control values. In addition, the percentage of REM sleep was consistently increased, as would be expected from previous research (Palagini et al., 2013; Paykel et al., 1995; Steiger and Kimura, 2010) . These findings were consistent with previous findings of reduced autonomic activity and increased REM sleep in bipolar subjects, but the research design and small numbers limited their significance. Mariani et al. (2012) reported a 'bedtime' HRV study of 12 patients suffering from bipolar disorders, aged between 18 and 65 years, in clinical states defined as euthymic, depressed, hypomanic or mixed. They were compared with 102 healthy control subjects. They found that 'most' (unspecified) RMSSD scores and measures of Sample Entropy for bipolar subjects were below the first quartile and/or median value of the control group. This study is very difficult to interpret because of the small number of bipolar subjects, the mixture of mental states being assessed, the heterogeneous nature of the bipolar diagnoses, the lack of data regarding medication use, the lack of detail regarding results and the uncertain comparability of multiple observations from a number of subjects. However, the trend in these findings was again towards a reduction in HRV in subjects suffering from bipolar mood disorders, during the 'bedtime' period.
Medication effects in HRV
Research has provided considerable evidence that antidepressant medications can exert significant effects upon HRV, but the differences between antidepressants are noteworthy. The effects of antipsychotic, anticonvulsant medications, lithium and benzodiazepines appear less intense than antidepressants, but the research findings exhibit significant variation. Davidson et al. (2005) found that venlafaxine was associated with a greater fall in HRV indices than paroxetine, while Van Zyl et al. (2008) found tricyclic antidepressants were associated with reductions in HRV indices over short recordings (2-40 minutes) but not long recordings (24 hours). SSRIs appeared to have minimal effects on HRV in both groups of recordings. Agelink et al. (2002) observed that reboxetine did not cause any significant changes in vagally mediated HRV indices, while Siepmann et al. (2004) found that moclobemide did not alter measures of HRV in 12 male volunteers (aged 22-29 years), compared with healthy volunteers. Kemp et al. (2010 Kemp et al. ( , 2011 found that tricyclic antidepressants were associated with decreased HRV, while SSRIs, mirtazapine and nefazodone had no significant effects. Subsequently, reported that escitalopram administered to 44 healthy subjects over the age of 25 years increased the HF (prominently parasympathetic) component of HRV, both at rest and during a period of psychological stress. Those subjects under 25 years did not exhibit any change, suggesting that differences in prefrontal maturation may be significant in this process. Udupa et al. (2011) , using brief ECG recordings, examined HRV parameters in subjects taking tricyclic antidepressants (n = 32) or SSRIs (n = 32). They found reductions in time and frequency measures with the use of tricyclic antidepressants but no change with SSRIs.
Antidepressant medications
More recently, Chappell et al. (2013) performed a randomized, controlled, subject-blind, two-period, cross-over study with 26 healthy subjects aged 50-65 years (to minimize gender effects) (Umetani et al., 1998; Voss et al., 2013) , using a placebo, duloxetine or escitalopram. They were sequentially exposed to escitalopram 20 mg daily or duloxetine 60 mg daily, each for 11 days, separated by 2 days of 'washout'. Twenty-four-hour ECG recordings were collected, and analysis revealed that time-based and frequency-based HRV measures were not significantly different between the baseline recordings and each of the medication exposed days. Terhardt et al. (2013) measured time and frequency dimension HRV parameters during brief observation in 28 healthy controls and 41 moderately depressed subjects, both during a drug-free period, and after 14 and 28 days of treatment with venlafaxine or mirtazapine. They found that HRV measures declined during treatment with either medication, while heart rate increased.
In a study of a very large cohort, Kemp et al. (2014a) found that a large range of antidepressant medications (tricyclic antidepressants, serotonin and noradrenaline reuptake inhibitors, SSRIs and a number of unspecified 'other antidepressants') all significantly suppressed HRV (measured as RMSSD and HF). The effect of the tricyclics was the greatest (Cohen's d for RMSSD = 0.81 and HF = 0.73) and the SSRIs the least (RMSSD = 0.28 and HF = 0.25).
Lithium, antipsychotic and anticonvulsant medications
The research into the effects of lithium and anticonvulsant medications (the latter used in the treatment of mood disorders) suggests absence of effect upon HRV. The findings for antipsychotic medications are more heterogeneous, and there is evidence that prolonged use of antipsychotic medications may result in a normalization of reduced HRV provoked by the relevant medications. Cohen et al. (2003) examined HRV in subjects taking lithium alone or combinations of lithium, sodium valproate, carbamazepine or olanzapine. They concluded that there was no medication effect upon the SDNN measure of HRV, including with lithium. Similarly, Lotufo et al. (2012) , in their meta-analysis, reported only very limited evidence of an effect of anticonvulsant medications upon HRV. Stefani et al. (2013) found that withdrawal of anticonvulsant medications was not associated with changes in HRV, and Henry et al. (2010) found that mood stabilizer or antipsychotic use had no significant effect upon HRV measures. Agelink et al. (2001) examined the effect of amisulpride, olanzapine, sertindole and clozapine upon HRV in subjects with schizophrenia, compared with control subjects. They found that only clozapine significantly reduced RMSSD, but the variation in all parameters measured was very large. Iwamoto et al. (2012) measured the effects of chlorpromazine and mepromazine (with 72% receiving both) upon HRV in 211 subjects suffering from schizophrenia and 44 control subjects. An ECG was recorded for 5 minutes under standardized conditions, with regularly paced breathing. They reported that the LF and HF powers were lower, but LF/HF ratios the same, in the schizophrenia subjects. This suggested a reduction in overall autonomic activity, without an alteration in sympathetic/parasympathetic balance. A negative correlation of antipsychotic dose effect upon LF + HF power was noted. The muscarinic effects of mepromazine and chlorpromazine may have contributed to this effect (Huang et al., 2013) .
Similarly, Linder et al. (2014) , in a carefully executed study, measured HRV parameters in 55 young, predominantly female patients (mean age = 33 ± 7 years, 67% female) suffering from bipolar disorders (I and II), who were taking antipsychotic medications. Current use of second-generation antipsychotics, but not first-generation antipsychotics (the numbers were relatively small), was associated with a reduction in SDNN and RMSSD and strongly related to dopamine receptor 2 affinity (paradoxically, given high affinity in firstgeneration antipsychotics). However, extended use of antipsychotics (up to 5 years) and the use of lithium or anticholinergic medications were not associated with significantly reduced HRV measures. Khaspekova et al. (2005) found improvement of HRV in a study of clonazepam in the management of paroxysmal atrial fibrillation. Komatsu et al. (1995) reported evidence that midazolam reduced LF elements of HRV and increased elements of HF, during anaesthesia. A lack of clarity about the impact of benzodiazepines upon HRV remains.
Benzodiazepines

Therapeutic interventions to enhance HRV
A number of treatment interventions have been considered to enhance HRV and thus inhibit the adverse effects of illness such as depressive and bipolar disorders. Exercise has shown promise (Soares-Miranda et al., 2014; Tonello et al., 2014) , but varying efficacy and differences in effect between resistance exercise and aerobic exercise (Kingsley and Figueroa, 2014) and time of day leave the benefits of exercise uncertain. HRV biofeedback has shown some positive effects upon HRV (Prinsloo et al., 2014; Wheat and Larkin 2010) , but the evidence is still limited. Acupuncture (Chung et al., 2014) has been employed with some encouraging but limited results, while the benefits of Yoga remain uncertain (Posadzki et al., 2015) . Mindfulness may also enhance HRV, but this remains uncertain (Nijjar et al., 2014) .
Conclusion
The ANS is central to physiological health and is regulated by central nervous system components which are fundamental to psychological functions. It is increasingly clear that major unipolar and bipolar mood disorders are associated with significant disruption of ANS activity. Whether these changes precede these disorders or persist during remission are important questions to be addressed. They also have implications for a variety of physiological functions such as cardiac function, energy regulation and gastrointestinal motility.
The changes in the operation of the ANS also offer a window into the neurophysiological changes which occur in the central ANS (insular cortex, cingulate cortex, medial and supraorbital prefrontal cortex, with links to hypothalamus, thalamus and periaqueductal grey). The ANS is heavily involved in the stress (or demand) response mechanisms and maintenance of optimal non-stress or vegetative functions. While sympathetic activity is essential for adequate responses to stress/demand, parasympathetic activity balances the potentially adverse effects of sympathetic drive (e.g. excessive arousal and reduced activity of non-essential functions) optimizing the physiological functioning of the ANS. As parasympathetic activity is more rapid and flexible than sympathetic drive, this component of the ANS provides significant modulation of function. A variety of medications, including many psychotropic drugs, also appear to adversely impact autonomic function, but the degree of effect varies widely among medications.
HRV offers a relatively simple, well-tolerated, non-invasive and inexpensive method for studying some of these pathophysiological processes. The results of research into HRV and mood disorders suggest a clear trend towards evidence of a negative association and particularly the dysregulation of parasympathetic activity. However, there has been considerable variation in these results and concerns about the validity of the interpretations made of the variables derived, making definitive conclusions difficult. Careful attention to the management of confounding variables through more substantial sample sizes, careful subject selection (particularly subjects not taking relevant medications), use of non-linear measures, appropriate statistical analyses (such as Propensity Score Matching and Inverse Probability Weighting) (Hogan and Lancaster, 2004; Kemp et al., 2014a Kemp et al., , 2014b Pearl, 2000; Voss et al., 2006; Williamson and Forbes, 2014) and greater consistency in research methodology would facilitate our knowledge of major mood disorders and their adverse effects upon this critically important component of central nervous system function.
Despite these limitations, the study of HRV has already contributed meaningfully to our understanding of the pathophysiology of mood disorders, their adverse effects upon a variety of physiological functions and the adverse effects of psychotropic medications. When combined with clinical and other psychophysiological research techniques, HRV provides a valuable tool for expanding our knowledge and management of these common and disabling mental disorders.
